← All trials
NCT06099535
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 18, 2021
- Primary completion
- Dec 29, 2022
- Completion date
- Apr 11, 2023
- First posted
- Oct 25, 2023
- Last posted
- Oct 25, 2023
- Enrollment
- 156
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Lynk Pharmaceuticals Co., LtdLead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.